The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Insights into MajesTEC-4: assessing the role of teclistamab as maintenance in patients with myeloma
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, highlights the rationale and design of the Phase III MajesTEC-4 study (NCT05243797) that will assess the role of teclistamab as maintenance therapy after autologous stem cell transplantation (autoSCT) in patients with newly diagnosed multiple myeloma. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen, BMS, Amgen, Roche, Pfizer, Sanofi, GSK: Honoraria, Other.
